11 Results for "

MLL-AF9 BMCs

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "MLL-AF9 BMCs" in MCE Product Catalog:

Cat. No.: HY-106850
CAS No.: 84472-85-5
Purity:  99.11%
Synonyms: AzdU; AzddU; CS-87
Target:  

HIV

Research Areas:  

Infection

3′-Azido-2′,3′-dideoxyuridine (AzdU) is a nucleoside analog of Zidovudine (HY-17413). 3′-Azido-2′,3′-dideoxyuridine is a potent inhibitor of human immunodeficiency virus (HIV) replication in human peripheral blood mononuclear cells (PBMC) with limited toxicity for human bone marrow cells (BMC) . 3′-Azido-2′,3′-dideoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
loading...
    loading...
Cat. No.: HY-129771
CAS No.: 676487-42-6
Target:  

Drug Derivative

Research Areas:  

Neurological Disease

3-Bromomethcathinone (3-BMC) hydrochloride is a drug derivative.
loading...
    loading...
Cat. No.: HY-19541A
CAS No.: 2147701-33-3
I-CBP112 hydrochloride is a selective inhibitor of CBP/P300 that directly binds their bromodomains (Kds = 142 and 625 nM, respectively). I-CBP112 significantly reduces the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. I-CBP112 increases the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin .
loading...
    loading...
Cat. No.: HY-146724
CAS No.: 2580940-76-5
Research Areas:  

Cancer

Dot1L-IN-7 (compound 25) is a potent and selective disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC50 of 1.0 μM. Dot1L-IN-7 selectively killed Mixed Lineage Leukemia (MLL)-AF9 without showing any effect on the growth of E2A-HLF cells .
loading...
    loading...
Cat. No.: HY-146187
CAS No.: 2417651-42-2
Research Areas:  

Cancer

Antitumor agent-69 (compound 12) is a potent inhibitor of protein-protein interaction between DOT1L and MLL-AF9/MLL-ENL, with Kis of 9 nM and 109 nM for AF9 and ENL, respectively. Antitumor agent-69 exhibits anticancer cellular activitiy .
loading...
    loading...
Cat. No.: HY-146663
CAS No.: 2410992-65-1
Target:  

Cholinesterase (ChE)

Research Areas:  

Neurological Disease

AChE/BChE-IN-3 (BMC-1) is a dual AChE and BChE inhibitor with IC50 values of 6.08 μM and 0.383 μM against electric eel AChE (elAChE) and equine serum BChE (eqBChE), respectively .
loading...
    loading...
Cat. No.: HY-146663A
CAS No.: 2410992-69-5
Target:  

Cholinesterase (ChE)

Research Areas:  

Neurological Disease

AChE/BChE-IN-3 (BMC-1) hydrochloride is a dual AChE and BChE inhibitor with IC50 values of 6.08 μM and 0.383 μM against electric eel AChE (elAChE) and equine serum BChE (eqBChE), respectively .
loading...
    loading...
Cat. No.: HY-146665
CAS No.: 2410992-68-4
Target:  

Cholinesterase (ChE)

Research Areas:  

Neurological Disease

AChE/BChE-IN-5 (BMC-16) is a dual AChE and BChE inhibitor with IC50 values of 266 nM and 10.6 nM against human AChE (hAChE) and human BChE (hBChE), respectively. AChE/BChE-IN-5 can cross the BBB .
loading...
    loading...
Cat. No.: HY-118848
CAS No.: 111525-11-2
A63162 is a specific 5-lipoxygenase (5-LOX) inhibitor. A63162 inhibits mitogen (PHA)-induced horse mononuclear cell (BMC) proliferation and inhibits Calcimycin (HY-N6687)-induced leukotriene LTB4 synthesis at the same concentration. A63162 can be used in the study of chronic obstructive pulmonary disease, arthritis and inflammatory bowel disease .
loading...
    loading...
Cat. No.: HY-146664
CAS No.: 2294963-47-4
Target:  

Cholinesterase (ChE)

Research Areas:  

Neurological Disease

AChE/BChE-IN-4 (BMC-3) is a dual AChE and BChE inhibitor with IC50 values of 792 nM and 2.2 nM against human AChE (hAChE) and human BChE (hBChE), respectively. AChE/BChE-IN-4 can cross the BBB .
loading...
    loading...
Cat. No.: HY-182019
HDAC11-IN-5 is a selective, potent and orally active HDAC11 inhibitor with an IC50 of 0.021 μM. HDAC11-IN-5 increases fatty acylation levels of substrate SHMT2 in AML cells. HDAC11-IN-5 induces apoptosis, G1 phase cell cycle arrest, ferroptosis, ROS production and terminal myeloid differentiation in AML cells. HDAC11-IN-5 demonstrates anti-tumor potency in an MLL-AF9-induced mouse AML model. HDAC11-IN-5 can be used for the research of cancer, such as acute myeloid leukemia .
loading...
    loading...
  • 1